Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?

Am J Ophthalmol. 2011 Sep;152(3):329-331. doi: 10.1016/j.ajo.2011.05.040.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Diabetic Retinopathy / drug therapy
  • Humans
  • Infant, Newborn
  • Macular Degeneration / drug therapy
  • Ophthalmology / standards
  • Practice Guidelines as Topic
  • Ranibizumab
  • Retinal Vein Occlusion / drug therapy
  • Retinopathy of Prematurity / drug therapy
  • Therapeutic Equivalency
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab